Zydus Lifesciences Reports on Business Responsibility, Highlights Water Conservation and GHG Emission Reductions for FY25-26

Zydus Lifesciences Reports on Business Responsibility, Highlights Water Conservation and GHG Emission Reductions for FY25-26​

Zydus Lifesciences Limited has released its Business Responsibility and Sustainability Report (BRSR) covering the financial year ended March 31, 2026. The report details the company’s operational footprint, workforce statistics, and commitment to environmental protection across its global operations, noting significant strides in energy efficiency and water management.

The company operates with a focus on three primary business segments: Pharmaceuticals (82.56% of turnover), Consumer Wellness (14.56%), and Medical Devices (2.88%). Zydus has established a robust operational presence both domestically and internationally, maintaining 38 plants and 26 offices across India, along with 6 international plants and 48 international offices. The company contributes 33.80% of its total turnover through exports.

As per the report, Zydus Lifesciences Ltd maintains a paid-up capital of `1,006.23 Million.

Key Sustainability and Environmental Commitments​

The company has implemented proactive measures across environmental stewardship, focusing on resource efficiency and waste reduction. A key component of this commitment is the adoption of Zero Liquid Discharge (ZLD) in manufacturing facilities, achieved through the use of reverse osmosis (RO) and ultra-filtration (UF) systems combined with a tertiary effluent treatment plant (ETP).

In terms of carbon footprint, total Scope 1 and Scope 2 GHG emissions reached 2,89,737 tCO2e for FY 2025-26, marking an improvement from the 2,61,631 tCO2e recorded in FY 2024-25. The emission intensity stood at 1.07 tCO2e per million revenue, down from 1.13 tCO2e/million revenue in the previous fiscal year.

The company’s commitment to circularity is evidenced by its waste management practices. Total waste generated amounted to 34,531.18 MT in FY 2025-26. Of this total, a substantial 24,001.48 MT was recycled, primarily related to plastic packaging under the Extended Producer Responsibility (EPR) framework.

Workforce and Social Governance Overview​

The company reported a workforce totaling 24,618 employees and 12,209 workers at the end of FY 2025-26. The internal wellbeing efforts showed improvements in operational costs. The cost incurred on wellbeing measures for both employees and workers decreased to 0.42% and 0.38%, respectively, compared to the previous fiscal year.

The company’s policies are covered by a comprehensive governance framework, which includes an active CSR and ESG committee. In line with social impact assessment (SIA) activities conducted by M/s SoulAce Consulting Pvt Ltd, the company has actively contributed towards the development of Zydus Lifesciences University in Gujarat to support regional economic growth.

Market Engagement and Stakeholder Metrics​

The organization maintains transparent engagement processes across all stakeholder groups, including patients, channel partners, suppliers, and regulators. The company’s commitment to responsible consumption is highlighted by a global pharmacovigilance policy implemented for drug products.

Regarding customer interactions, 1,480 complaints were received from general consumers in FY 2025-26, compared to 1,567 in the previous year. Furthermore, 39 voluntary recalls were initiated in the current fiscal year due to market complaints regarding products out of specification or regulatory recommendations.

Operational Efficiency and Supply Chain Inputs (FY 2025-26 vs FY 2024-25)​

Industry Adherence and Safety​

The company operates under a comprehensive occupational health and safety management system aligned with ISO 45001:2018, utilizing processes such as HAZOP (Hazard operating procedures) and Risk Assessment to identify risks. Key performance indicators for the year included:

• Lost Time Injury Frequency Rate (LTIFR): 0.08 (Employees); 0 (Workers).
• Total Recordable Work-Related Injuries: Employees reported 6 injuries, while workers recorded 0 injuries.

The company has also provided detailed information on its regulatory compliance status and engagement with industry associations, maintaining affiliations with fourteen trade and industry chambers/associations, including the Federation of Indian Chambers of Commerce and Industry (FICCI) and The Indian Drug Manufacturers Association.

ZYDUSLIFE Stock Price Movement​

Zydus Lifesciences Limited shares closed today after shedding 0.53% to settle at ₹1150.8. The stock saw intense volume, with 824,192 shares traded throughout the day and trading within a band ranging from ₹1145 to ₹1164.9.